益气清湿化瘀法时效调控PID反复发作患者正负免疫通路的研究
项目来源
国（略）科（略）(（略）C（略）
项目主持人
魏（略）
项目受资助机构
成（略）药（略）
立项年度
2（略）
立项时间
未（略）
项目编号
8（略）3（略）
项目级别
国（略）
研究期限
未（略） （略）
受资助金额
7（略）0（略）
学科
医（略）-（略）-（略）科（略）
学科代码
H（略）1（略）1（略）
基金类别
面（略）
关键词
正（略）通（略） （略）合（略）;（略）炎（略）作（略）益（略）化（略）;（略）免（略） （略）医（略）法（略）盆（略）复（略）;（略）清（略）法
参与者
王（略）怡（略）友（略）；（略）曾（略）王（略）张（略）田（略）
参与机构
成（略）药（略）；南京中医药大学
项目标书摘要：盆腔（略）盆腔炎性疾病严重后（略）杂，病情缠绵难愈，（略）康，是临床治疗亟待（略）在前期研究取得明显（略）清湿化瘀综合方案防（略）合治，防治并重，以（略）究对象，育龄期健康（略）Rs/MyD88-（略）疫调控通路为研究环（略）流式细胞术检测外周（略）的蛋白含量,RT-（略）细胞中TLR2、4（略）A法检测血清MyD（略）、suPAR、hs（略）IL-6值的变化，（略）方案防治PID反复（略）腔慢性炎症特异性诊（略）证疗效评价方法分析（略）中医特色、科学客观（略）依据。
Applicati（略）: Recurre（略）nflammato（略）PID)is a （略）plication（略）ch pathog（略）eficiency（略） intermin（略）t the dis（略）ficult to（略）ffected t（略）productiv（略）riously.T（略）roposes a（略）d control（略）tonifying（略）elling da（略）revent an（略）rrent PID（略）udy,PID r（略）tients to（略）h group a（略）women of （略）g age to （略）ntrol gro（略）o observe（略）yD88-Gas6（略）ve immune（略） pathways（略） blood sa（略）tect prot（略） of TLR2,（略）ripheral （略）cytes usi（略）ometry,to（略） contents（略）mRNA a in（略） blood le（略） RT-PCR t（略）nd to det（略）hanges of（略）/TAM,suPA（略）F alpha,I（略）y ELISA m（略）plore the（略）c targets（略）g for the（略）ndexs to （略）ronic inf（略）o,and to （略） research（略）raditiona（略）ic evalua（略）rd.We are（略）sh and pe（略）cientific（略）ive exper（略）dence for（略）c evaluat（略）rrent PID（略）
项目受资助省
四（略）
项目结题报告(全文)
PID反复发作病情（略）的生殖健康和生活质（略）的疑难问题。PID（略）能不足或紊乱有紧密（略）疫功能有赖于正向免（略）与平衡。本课题通过（略）方案治疗PID反复（略）法，前后自身对照，（略）D反复发作的疗效。（略）作患者正负免疫通路（略） 样受体,MyD8（略）CRP,Gas6,（略）IL-17,IL-（略）前后的变化，并与健（略）发现益气清湿化瘀综（略）复发作的疗效机制。（略）反复发作患者共10（略）脱落8例，有效病例（略）湿化瘀综合方案治疗（略）、中医证候、体征及（略），并得出分析结果。（略）疗 PID 反复发（略）中医证候以及体征方（略）月后复发率为7.4（略）.59%,无明显不（略）反复发作患者正负免（略）疗前后的变化，并与（略），益气清湿化瘀综合（略）发作患者可通过下调（略）s表达、MyD88（略）IL-17、IL-（略）PAR、hs-CR（略）受体负向免疫通路相（略）r、sAx1)表达（略）察suPAR与hs（略）发作患者血清中表达（略）清浓度与PID反复（略）相关性，运用ROC（略）uPAR 比 hs（略）诊断效能和特异度,（略）为 PID 反复发（略）标之一。
1. Lindberg, S.; Copolovici, D.M.; Langel, Ü. (2011). Therapeutic delivery opportunities, obstacles and applications for cell-penetrating peptides. Therapeutic Delivery, 2, 71−82.
2.Acupuncture for chronic pelvic pain in patients with SPID A protocol for systematic review and meta-analysis
- 关键词：
- acupuncture; chronic pelvic pain; meta-analysis; protocol; sequelae ofpelvic inflammatory disease; systematic review;WOMEN
Background: Chronic pelvic pain (CPP) is one of the common sequela of pelvic inflammatory disease, the pathological factors are adhesions, scarring and pelvic congestion which caused by inflammation, often cause abdominal pain and lumbosacral soreness, and aggravated after fatigue, sexual intercourse and during menstruation. It is difficult to treat because special pathological changes. Although acupuncture has gained increased popularity for the management of CPP, evidence regarding its efficacy is lacking. Therefore, a systematic review of acupuncture for chronic pelvic pain in patients with SPID is required to provide available evidence for further study. Methods and analysis: We will conduct a systematic review of randomized controlled trials (RCTs) that investigate the effect and safety of acupuncture for the treatment of chronic pelvic pain patients with SPID. We will electronically search the literature in the databases of PubMed, the Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, the Web of Science, China National Knowledge Infrastructure (CNKI), Wan-fang Digital Periodicals, Chinese Biomedical Literature Database (CBM), Chinese Scientific Journal Database (VIP) and select eligible articles. Data extraction will be conducted by 2 researchers independently, and risk of bias of the meta-analysis will be evaluated based on the Cochrane Handbook for Systematic Reviews of Interventions. The primary outcomes will be total effective rate and VAS pain score, and the secondary outcomes include the recurrence rate and adverse reaction. All data analysis will be conducted by software Review Manager V.5.3. Results: This study will provide the latest analysis of the currently available evidence for the efficacy of acupuncture for chronic pelvic pain in patients with SPID. PROSPERO registration number: CRD42020193826.
...3.Detoxification therapy of traditional Chinese medicine for genital tract high-risk human papillomavirus infection: A systematic review and meta-analysis
- 关键词：
- CYTOLOGY; CANCER; CIN
BackgroundPersistence of high-risk human papillomavirus (hr-HPV) infections is the most critical risk factor for cervical intraepithelial neoplasia (CIN) and cervical cancer (CC). Treatment of persistent oncogenic HPV-positive women after 12-24 months follow-up is still controversy. Detoxification therapy of Chinese medicine (DTCM) has been conducted recently. However, the conclusions are still unclear. We planned to conduct a systematic review and meta-analysis to explore DTCM in the treatment of persistent hr-HPV infections.MethodsNine electronic databases were systematically searched from their inception to 30 September 2018. Randomized controlled trials comparing DTCM with follow-up or placebo were included. Risk of bias was assessed by the Cochrane 'Risk of Bias' tool. Review Manager 5.3 was used for statistical analyses. Relative ratios (RR) and 95% confidence intervals were used for dichotomous data, and the mean difference (MD) was used for continuous data. We assessed the quality of trials by the GRADE.ResultsSeventeen RCTs from 2011 to 2018 with 1906 participants were included. The evidence showed that DTCM had a pooled efficacy difference in favor of increasing the HPV clearance rate compared to placebo groups (RR = 2.62, 95% CI 1.28 to 5.33, very low quality) and follow-up groups (RR = 1.88, 95% CI 1.60 to 2.22, low quality). The median HPV persistence tended to decline from 50% within six months to 41.5% at 12 months, and 31.5% at 24 months. A significantly increased regression rate of CIN was found in the DTCM compared with placebo groups (RR = 3.61, 95% CI 1.21 to 10.83, very low quality) and follow-up groups (RR = 1.79, 95% CI 1.31 to 2.45, very low quality). Additionally, we found DTCM have an impact on TNF-alpha (MD = 2.99, 95% CI 1.90 to 4.07; very low quality), IFN-alpha (MD = 3.47, 95% CI 2.42 to 4.52; very low quality), CD4+/CD8+ cells (MD = 0.21, 95% CI 0.05 to 0.37; very low quality) compared with follow up groups in some trials with small sample sizes. The major adverse events were genital mucosal irritation symptoms (10%, 5/50).ConclusionsDTCM have favorable outcomes on improving the HPV clearance rate, increasing the regression rate of CIN, and impacting the proportion of some immune cells and cytokine levels. However, most of the evidence was of low quality. Any future high-quality trials and a more extended follow-up period of 24 months or more should be performed.
...4.Detoxification therapy of traditional Chinese medicine for genital tract high-risk human papillomavirus infection: A systematic review and meta-analysis
- 关键词：
- CYTOLOGY; CANCER; CIN
BackgroundPersistence of high-risk human papillomavirus (hr-HPV) infections is the most critical risk factor for cervical intraepithelial neoplasia (CIN) and cervical cancer (CC). Treatment of persistent oncogenic HPV-positive women after 12-24 months follow-up is still controversy. Detoxification therapy of Chinese medicine (DTCM) has been conducted recently. However, the conclusions are still unclear. We planned to conduct a systematic review and meta-analysis to explore DTCM in the treatment of persistent hr-HPV infections.MethodsNine electronic databases were systematically searched from their inception to 30 September 2018. Randomized controlled trials comparing DTCM with follow-up or placebo were included. Risk of bias was assessed by the Cochrane 'Risk of Bias' tool. Review Manager 5.3 was used for statistical analyses. Relative ratios (RR) and 95% confidence intervals were used for dichotomous data, and the mean difference (MD) was used for continuous data. We assessed the quality of trials by the GRADE.ResultsSeventeen RCTs from 2011 to 2018 with 1906 participants were included. The evidence showed that DTCM had a pooled efficacy difference in favor of increasing the HPV clearance rate compared to placebo groups (RR = 2.62, 95% CI 1.28 to 5.33, very low quality) and follow-up groups (RR = 1.88, 95% CI 1.60 to 2.22, low quality). The median HPV persistence tended to decline from 50% within six months to 41.5% at 12 months, and 31.5% at 24 months. A significantly increased regression rate of CIN was found in the DTCM compared with placebo groups (RR = 3.61, 95% CI 1.21 to 10.83, very low quality) and follow-up groups (RR = 1.79, 95% CI 1.31 to 2.45, very low quality). Additionally, we found DTCM have an impact on TNF-alpha (MD = 2.99, 95% CI 1.90 to 4.07; very low quality), IFN-alpha (MD = 3.47, 95% CI 2.42 to 4.52; very low quality), CD4+/CD8+ cells (MD = 0.21, 95% CI 0.05 to 0.37; very low quality) compared with follow up groups in some trials with small sample sizes. The major adverse events were genital mucosal irritation symptoms (10%, 5/50).ConclusionsDTCM have favorable outcomes on improving the HPV clearance rate, increasing the regression rate of CIN, and impacting the proportion of some immune cells and cytokine levels. However, most of the evidence was of low quality. Any future high-quality trials and a more extended follow-up period of 24 months or more should be performed.
...